U.S. Budget Airlines Seek $2.5 Billion Government Aid Amid Rising Jet Fuel Costs 
Brazil Pension Fund Crackdown After Banco Master Collapse Raises Investment Concerns 
Brazil Blocks Prediction Market Platforms, Tightens Derivatives Trading Rules 
$16B Michigan Data Center Project Boosts U.S. AI Infrastructure Expansion 
PLS Reports Record Lithium Output as EV Demand Fuels Market Growth 
Taiwan Court Fines Tokyo Electron Unit $4.78M in Major TSMC Trade Secrets Case 
Amazon Stock Rises as Meta Expands AWS Partnership for AI Infrastructure 
Judge Dismisses Elon Musk’s Fraud Claims Against OpenAI, Trial to Proceed on Remaining Allegations 
Intel Stock Surges as AI Chip Demand Drives Strong Q2 Forecast 
DeepSeek Launches V4 AI Models with Enhanced Reasoning and 1M Token Context Window 
Kia Cuts EV Prices in Europe as Chinese Carmakers Intensify Competition 
U.S. Demand for Alternative Satellite Providers Remains Strong Amid SpaceX Regulatory Push 
Strait of Hormuz Shipping Crisis Deepens as Traffic Plunges Amid Iran-U.S. Tensions 
Why Global Web3 Projects Can't Afford to Skip South Korea: TokenPost Unveils Data-Driven Entry Solutions 
U.S. Raises Alarm Over Chinese AI Firms’ Alleged IP Theft Through Model Distillation 
Sun Pharma to Acquire Organon in $11.75 Billion Deal to Boost Global Women’s Health Portfolio 
Hyundai Plans 20 New Models in China to Boost EV Strategy and Market Share 
CRANBURY, N.J., May 10, 2017 -- Amicus Therapeutics (Nasdaq:FOLD), a global biotechnology company at the forefront of rare and orphan diseases, today announced that Chip Baird, Chief Financial Officer, will present at two upcoming investor conferences:
- Bank of America Merrill Lynch 2017 Health Care Conference in Las Vegas, NV on Wednesday, May 17, 2017 at 5:00 p.m. P.T.
- UBS Global Healthcare Conference 2017 in New York, NY on Monday, May 22, 2017 at 1:00 p.m. E.T.
A live webcast of both presentations can be accessed through the Investors section of the Amicus Therapeutics corporate web site at http://ir.amicusrx.com/events.cfm, and will be archived for 90 days.
About Amicus Therapeutics
Amicus Therapeutics (Nasdaq:FOLD) is a global biotechnology company at the forefront of therapies for rare and orphan diseases. The Company has a robust pipeline of advanced therapies for a broad range of human genetic diseases. Amicus’ lead programs in development include the small molecule pharmacological chaperone migalastat as a monotherapy for Fabry disease, SD-101 for Epidermolysis Bullosa (EB), as well as novel enzyme replacement therapy (ERT) and biologic products for Fabry disease, Pompe disease, and other rare and devastating diseases.
FOLD–G
CONTACTS: Investors/Media: Amicus Therapeutics Sara Pellegrino Senior Director, Investor Relations [email protected] (609) 662-5044
